Best of ASCO - 2014 Annual Meeting

 

Welcome

Pharmacology

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A pilot, phase I clinical trial to determine the biological effects of hydroxychloroquine (HCQ) on par-4 levels in patients with surgically removable solid tumors.

Peng Wang

e14555

An open-label, randomized cross-over bioavailability and extension study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours.

Christopher G. C. A. Jackson

2569

Association of thymidylate synthase (TYMS) polymorphism with adverse events (AEs) of 5-FU/capecitabine (CAP) in pts with GI cancers.

Ruchi Hamal

e14561

Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.

Dawei Xuan

2574

Development of TRIB3 as a novel preclinical and clinical pharmacodynamic biomarker for ABTL0812.

Héctor Pérez-Montoyo

e14556

Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades.

Nauman S Siddiqui

2576

Effects of rifampin on the pharmacokinetics of copanlisib, a novel pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in cancer patients.

Anna Spreafico

e14559

First-in-human, first-in-class phase 1a study of BXQ-350 for solid tumors and gliomas.

Olivier Rixe

2517

Gene expression and cytokine modulation in a first in human (FIH) study of a pan BET inhibitor ABBV-075 in solid tumors.

Bert H. O'Neil

2570

Impact of curcumin with and without (+/-) piperine on tamoxifen exposure.

Gerardus Hussaarts

2572

Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).

Whitney Paige Kirschbrown

2564

Pharmacology, ADME and selectivity profile of the next generation CXCR4 antagonist balixafortide.

Garry Douglas

e14553

Predicting 5-Fluorouracil related severe toxicity with DPD functional tests in plasma, fresh saliva and dried saliva samples.

Gilberto Schwartsmann

e14563

Preliminary single-dose clinical pharmacokinetics of an anti–PD-L1 Probody therapeutic (Pb-Tx) in cancer patients.

Mark Stroh

e14558

Progress in record numbers of approved therapies for gynecologic cancers: The lack of upfront approval for newly diagnosed cases.

Alisa Goldrich

e14551

Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.

Yulia Vugmeyster

2566

Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: Results of a phase I exposure escalation study.

Lemonitsa H. Mammatas

e14560

TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.

Jie Yu

2567

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy: A case-control study in a Northern Italy Cancer Centre.

Francesco Iachetta

2573

The effect of patient-to-patient variability in drug response on combination cancer therapies, from 1961 to today.

Adam Christopher Palmer

e14552

The NantOmics Pharmacogenomics Test: An integrative panomic approach to pharmacogenomics screening.

Camille Schwartz

2575

The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study.

Michael Michael

2563

Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) in routine practice in an oncology service. preliminary results.

Manuel Sureda

2571

Tozuleristide pharmacokinetics from phase 1 studies in adult and pediatric subjects with central nervous system tumors undergoing surgery.

Dennis Michael Miller

e14562

Unexpected pharmacokinetics of evofosfamide observed in phase III MAESTRO study.

Jack P. Higgins

2568

Validation of a new model for estimating glomerular filtration rate in patients with cancer.

Edward Williams

2565